SBSDS: System Biology of Spleen Deficiency Syndrome

Sponsor
Beijing University of Chinese Medicine (Other)
Overall Status
Unknown status
CT.gov ID
NCT02915393
Collaborator
(none)
90
39

Study Details

Study Description

Brief Summary

Spleen Deficiency Syndrome(SDS)is a widely researched issue, but due to the limitations of the research methods, the scientific mechanism of SDS is biased and not comprehensive. SDS would be researched in this project deeply and systematically with modern life-scientific methods. Based on the previous work, the participants, with SDS, suffering from Qi deficiency syndrome--chronic superficial gastritis--chronic atrophic gastritis--gastric cancer would be included, and the corresponding research would be conducted at the molecular-cell-gastric tissue level, and at the same time, systematical biological database of SDS would be built by systematical biological methods, such as pioneered SPARS sequencing technology created in our research group, proteomics and metabonomics. Under the above work, the investigators would conduct data mining and molecular network analysis, and then verify the key functions. By analyzing the systematical biological features of syndrome and its relationships with constitution and disease, this study would provide a new basis for objective reality of syndrome, and also offer a crucial premise of revealing biological basis for syndrome correctly, which is of important theoretical and practical significance.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    90 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Cross-Sectional
    Official Title:
    System Biology Research of Spleen Qi Deficiency Associated "Qi Deficiency Constitution-Disease"
    Study Start Date :
    Sep 1, 2016
    Anticipated Primary Completion Date :
    Sep 1, 2017
    Anticipated Study Completion Date :
    Dec 1, 2019

    Arms and Interventions

    Arm Intervention/Treatment
    Healthy Volunteers (BC)

    Healthy Volunteers with Balanced Constitution(n=10).

    Healthy Volunteers(QC)

    Healthy Volunteers with Qi Deficiency Constitution(n=10).

    Healthy Volunteers(DC)

    Healthy Volunteers with Damp-heat Constitution(n=10).

    Superficial Gastritis(SDS)

    Superficial Gastritis with Spleen-qi Deficiency Syndrome(n=10).

    Superficial Gastritis(DS)

    Superficial Gastritis with Damp-heat Syndrome(n=10).

    Atrophic Gastritis(SDS)

    Atrophic Gastritis with Spleen-qi Deficiency Syndrome(n=10).

    Atrophic Gastritis(DS)

    Atrophic Gastritis with Damp-heat Syndrome(n=10).

    Gastric Cancer(SDS)

    Gastric Cancer with Spleen-qi Deficiency Syndrome(n=10).

    Gastric Cancer(DS)

    Gastric Cancer with Damp-heat Syndrome(n=10).

    Outcome Measures

    Primary Outcome Measures

    1. Examination of the stomach with an endoscope. [at the beginning of the enrollment]

      Endoscopic diagnosis standard of chronic gastritis according to Chinese Society of Digestive Endoscopy.

    2. Pathological biopsy of gastric mucosa. [at the beginning of the enrollment]

      Pathological diagnosis standard of chronic gastritis according to Chinese Society of Gastroenterology.Pathological diagnosis standard of gastric cancer according to Ministry of Health P.R.China

    3. Detection of helicobacter pylori by Urea Breath Test(UBT) [at the beginning of the enrollment]

    Secondary Outcome Measures

    1. Analysis of gastric mucosa/venous blood/urine by system biology techniques [Three measurements within 1 year]

    2. Constitutional classification of TCM assessed by the Traditional Chinese Medicine Physical Constitution Scale [at the beginning of the enrollment]

    3. TCM syndrome type diagnosed by two professional TCM doctors [at the beginning of the enrollment]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Aged between 18 and 65 years.

    • No apparent abnormality in the routine blood test, urinalysis, routine stool & fecal occult blood test, biochemical test, chest radiograph and electrocardiogram(ECG).

    • The endoscopic diagnoses of chronic superficial gastritis, chronic atrophic gastritis and gastric cancer conform to the corresponding pathological diagnoses

    • TCM diagnoses of Spleen-qi Deficiency Syndrome or Spleen Damp-heat Syndrome.

    • Voluntary participation.

    • Having given written informed consent.

    Exclusion Criteria:
    • Gastropathy with special causes, such as acute gastritis, gastrinoma, chronic gastritis resulting from special causes (like granulomatous gastritis, lymphocytic gastritis, eosinophilic gastritis, gastritis after gastric operation) peptic ulcer, other malignant tumors of stomach (like gastric lymphoma, gastri stromal tumor, carcinoid tumor, malignant hemangioma, squamous-cell carcinoma, primary gastric choriocarcinoma and metastatic gastric tumor), benign gastritic tumors that originate from epithelium or submucosa (epithelial tumors like adenomatous polyps and hyperplastic polyps, stromal tumors like benign stromal tumor, neuronal tumor and pseudolymphoma).

    • Combined with other digestive diseases (like gastroesophageal reflux, esophageal varices, acute and chronic hepatitis and cirrhosis arising from various causes, acute/chronic pancreatitis and acute/chronic cholecystitis).

    • Combined with other severe systemic diseases such as respiratory failure, severe cardiovascular and cerebrovascular, immune system, urinary and mental disorders diseases.

    • Pregnancy, or planning pregnancy during the trial or within three month period thereafter.

    • Participation in any clinical trial including blood sampling and/or administration of substances up to 90 days before Day 01 of this study.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Beijing University of Chinese Medicine

    Investigators

    • Principal Investigator: Anlong Xu, Beijing University of Chinese Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Anlong Xu, President, Beijing University of Chinese Medicine
    ClinicalTrials.gov Identifier:
    NCT02915393
    Other Study ID Numbers:
    • 81430099
    First Posted:
    Sep 27, 2016
    Last Update Posted:
    Sep 27, 2016
    Last Verified:
    Sep 1, 2016
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Keywords provided by Anlong Xu, President, Beijing University of Chinese Medicine
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 27, 2016